The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick pickspolarean Regulatory News (POLX)

Share Price Information for polarean (POLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.05
Bid: 4.00
Ask: 4.10
Change: 0.60 (17.39%)
Spread: 0.10 (2.50%)
Open: 3.50
High: 4.75
Low: 4.05
Prev. Close: 3.45
POLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Directorate Change

27 Sep 2023 13:59

RNS Number : 8750N
Polarean Imaging PLC
27 September 2023
 

Polarean Imaging Plc

("Polarean" or the "Company")

 

Directorate appointment

 

Polarean Imaging plc (AIM: POLX), a commercial-stage medical device leader in advanced magnetic resonance imaging ("MRI") of the lungs, announces the appointment of William Blair ("Bill") as an Independent Non-Executive Director ("NED") to the Board of Polarean with immediate effect.

 

Bill is an investment professional, board director and executive with over 30 years of experience in investment banking, fund management, venture capital and private equity, with particular expertise in advising smaller and AIM-listed healthcare companies.

 

He currently serves as a NED and Chair of the Audit Committee at North East Finance, which invested £160m in a portfolio of companies ranging from micro-companies to those now listed on the London Stock Exchange. in the North East of England and the Tees Valley. Since July 2020, Bill has also served as an NED for Iksuda Therapeutics, a biotechnology company focused on developing antibody-drug-conjugate therapies, providing strategic advice and support on funding options and exit strategy. Bill is also currently a director at HVS Advisers, providing strategic advice to venture capital funds, institutions and SMEs (small and medium enterprises), and is a member of the Investment Advisory Board at the Pioneer Group Life Sciences Fund.

 

Bill will be appointed to the Board on the same basis as regards voting and term of appointment as the Company's existing Non-Executive Directors. He will be subject to the same requirements as contained in the Articles of Association of the Company for such appointment to be approved at the next Annual General Meeting of the Company and will be subject to the same requirements for retirement by rotation as the other Directors.

 

500,000 share options over ordinary shares in the Company (the "Share Options") have been granted to Bill. The Share Options will be exercisable at a price of 52p each per ordinary share in the Company and will vest 25% on 27 September 2024 with the remaining Share Options vesting in equal portions on the last day of each calendar month over the period of 36 months starting on 31 October 2024.

 

Notifications have been made in accordance with the requirements of the UK Market Abuse Regulation in respect of the PDMR and further details can be found by following this link: https://www.polarean-ir.com/content/investors/shareholder-information

 

Christopher von Jako, Ph.D., CEO of Polarean, said: "We are delighted to welcome Bill to the Board of Polarean. We felt it was important to have someone with further experience of the UK healthcare sector and with AIM-listed companies on the Board. Following conversations with Amati Global Investors, our largest shareholder, and several other shareholders, we identified Bill as the ideal candidate, given his deep understanding of the UK investor landscape and vast experience with AIM.

 

"We believe Bill's expertise will be invaluable to us as we continue the commercialisation of XENOVIEW and look to address the unmet medical needs of patients suffering with chronic respiratory diseases. As a team we look forward to his strategic advice helping us identify and evaluate the various financing options for the Company."

 

William Blair, Non-Executive Director of Polarean, said: "I am pleased to be joining the Board of Polarean, and to be able to share my experience as an investment professional and adviser to innovative companies. I am excited by Polarean's technology and its potential in both pulmonary and cardio-pulmonary medicine, and look forward to working with the other Board members to take the Company forward."

 

Additional Information

 

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Mr. William Taninhill Blair, aged 68:

 

Current Directorships

Previous Directorships or Partnerships (previous 5 years)

HVS Advisers Limited

North East Finance (Hold co) Limited

North East Finance (Sub co) Limited

North East Technology (GP) Limited

 

Bridge Valley Ventures

Iksuda Therapeutics Limited

 

 

 

 

 

Save as disclosed above there are no additional disclosures to be made in accordance with Rule 17 or Schedule Two paragraph (g) of the AIM Rules for Companies.

 

 

Enquiries: 

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Christopher von Jako, Ph.D, Chief Executive Officer

Via Walbrook PR

Charles Osborne, Chief Financial Officer

 

 

Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)

+44 (0)20 7710 7600

Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)

Nick Adams / Nick Harland (Corporate Broking)

Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Anna Dunphy / Phillip Marriage

Mob: +44 (0)7876 741 001 / +44 (0)7867 984 082

 

About Polarean (www.polarean.com)

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionise pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung ventilation, diagnose disease, characterise disease progression, and monitor response to treatment. By researching, developing, and commercialising novel imaging solutions with a non-invasive and radiation-free functional imaging platform. Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarisation science and has successfully developed the first and only hyperpolarised MRI contrast agent to be approved in the United States. The company also commercialises systems (such as the HPX hyperpolarisation system), accessories (such as Xe-specific chest coils and phantoms) and FDA-cleared post-processing software (to support ventilation defect analysis), to support fully integrated modern respiratory imaging operations.

 

 

XENOVIEW IMPORTANT SAFETY INFORMATION

 

Warnings and Precautions

Risk of Decreased Image Quality from Supplemental Oxygen: Supplemental oxygen administered simultaneously with XENOVIEW inhalation can cause degradation of image quality. For patients on supplemental oxygen, withhold oxygen inhalation for two breaths prior to XENOVIEW inhalation, and resume oxygen inhalation immediately following the imaging breath hold.

 

Risk of Transient Hypoxia: Inhalation of an anoxic gas such as XENOVIEW may cause transient hypoxemia in susceptible patients. Monitor all patients for oxygen desaturation and symptoms of hypoxemia and treat as clinically indicated.

 

Adverse Reactions

Adverse Reactions in Adult Patients: The adverse reactions (> one patient) in efficacy trials were oropharyngeal pain, headache, and dizziness. Adverse Reactions in Paediatric and Adolescent Patients: In published literature in paediatric patients aged 6 to 18, transient adverse reactions were reported: blood oxygen desaturation, heart rate elevation, numbness, tingling, dizziness, and euphoria. In at least one published study of paediatric patients aged 6 to 18 years, transient decrease in SpO2% and transient increase in heart rate was reported following hyperpolarised xenon Xe 129 administration. XENOVIEW is not approved for use in paediatric patients less than 12 years of age.

 

Please see full prescribing information at www.xenoview.net

 

PLC-RNS-2323

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAPPUMABUPWGPM
Date   Source Headline
30th Jul 20193:18 pmRNSHolding(s) in Company
30th Jul 20192:25 pmRNSHolding(s) in Company
29th Jul 20195:31 pmRNSHolding(s) in Company
25th Jul 20193:31 pmRNSResult of AGM
24th Jul 20192:45 pmRNSExercise of Warrants
22nd Jul 201910:00 amRNSPlacing to raise £2.1 million
11th Jul 20197:00 amRNSNew System Order
27th Jun 20197:00 amRNSFinal Results
13th Jun 20195:02 pmRNSInvestor Symposium presentations available online
11th Jun 20197:00 amRNSPhase III Clinical Trials - Update
5th Jun 20197:00 amRNSNew System Order
23rd May 20193:26 pmRNSGrant of Share Options
23rd May 20197:00 amRNSLondon Investor Symposium
21st May 20197:00 amRNS3rd tranche of $3m pediatric study grant confirmed
13th May 20197:00 amRNSClinical trial update
30th Apr 20197:00 amRNSTotal Voting Rights
29th Apr 20197:00 amRNSAppointment of Chief Financial Officer
2nd Apr 20197:00 amRNSExercise of Warrants
1st Apr 20197:00 amRNSAmphion Innovations - Pledge of Polarean shares
15th Feb 20197:00 amRNSNew System Order
24th Jan 20197:00 amRNSAppointment of Nominated Adviser and Broker
21st Jan 20193:36 pmRNSHolding(s) in Company
3rd Jan 20197:00 amRNSHolding(s) in Company
28th Dec 20182:52 pmRNSResult of General Meeting and Total Voting Rights
11th Dec 20187:05 amRNSInvestment in Polarean & Loan Facility Repayment
11th Dec 20187:00 amRNSConditional Fundraise to raise US$4 million
13th Nov 20187:00 amRNSLicencing Agreement with Duke University
6th Nov 20187:00 amRNSCompany update
5th Nov 20187:00 amRNSNominated Adviser Status
3rd Oct 20187:00 amRNSDelivery of Xenon Polariser
23rd Aug 20187:00 amRNSFIRST PATIENT IN PHASE III FDA CLINICAL TRIAL
22nd Aug 20187:00 amRNSHalf-year Report
27th Jul 20187:00 amRNSCompany update
18th Jul 20182:28 pmRNSResult of AGM
17th Jul 20182:49 pmRNSHolding(s) in Company
10th Jul 20183:22 pmRNSResult of Placing
9th Jul 20182:41 pmRNSProposed Placing to raise a minimum of £0.78m
21st Jun 201810:12 amRNSHolding(s) in Company
19th Jun 20184:40 pmRNSSecond Price Monitoring Extn
19th Jun 20184:35 pmRNSPrice Monitoring Extension
19th Jun 20187:00 amRNSInvestor Symposium
13th Jun 20187:00 amRNSFinal Results
6th Jun 20187:00 amRNSDelivery of Xenon Polariser
31st May 20187:00 amRNSLondon Investor Symposium
22nd May 20187:00 amRNSDelivery of Xenon Polariser
20th Apr 20187:00 amRNSGrant of Share Options
17th Apr 20187:00 amRNSPolarean technology used in severe asthma study
29th Mar 20187:00 amRNSAIM Admission & First Day of Dealings
29th Mar 20187:00 amRNSUpdate on Polarean Imaging IPO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.